<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681978</url>
  </required_header>
  <id_info>
    <org_study_id>RIVENDEL</org_study_id>
    <nct_id>NCT02681978</nct_id>
  </id_info>
  <brief_title>Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease</brief_title>
  <acronym>RIVENDEL</acronym>
  <official_title>Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of ivabradine on endothelial function in patients with
      coronary artery disease (CAD) after complete revascularization with percutaneous coronary
      angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive
      ivabradine 5 mg twice daily or to continue with standard medical therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation of the brachial artery</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with flow-mediated dilation of the brachial artery &lt;7%</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium-independent dilation of the brachial artery</measure>
    <time_frame>8 weeks</time_frame>
    <description>Dilation of the brachial artery after administration of 0.5 mg sublingual nitroglycerin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between heart rate and flow-mediated dilation of the brachial artery</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ivabradine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivabradine 5 mg twice daily + standard medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 5 mg twice daily</description>
    <arm_group_label>Ivabradine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard medical therapy</intervention_name>
    <description>Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions</description>
    <arm_group_label>Ivabradine group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of stable coronary disease

          -  complete coronary revascularization with PCI at least 1 month prior to recruitment

          -  sinus rhythm

          -  absence of anginal symptoms

        Exclusion Criteria:

          -  resting heart rate &lt;60 beats per minute

          -  severe reduction of left ventricle ejection fraction (&lt;40%)

          -  coronary artery by-pass surgery

          -  myocardial infarction, stroke or cerebral transient ischemic attack within the
             previous 6 months

          -  implanted pacemaker, cardioverter, or defibrillator

          -  sick sinus syndrome

          -  sinoatrial block

          -  congenital long QT

          -  complete atrioventricular block
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Mangiacapra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Campus Bio-Medico University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campus Bio-Medico University</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Germano Di Sciascio</investigator_full_name>
    <investigator_title>Prof. Germano Di Sciascio</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

